Conmed Secures $450M Loan to Repurchase 2026 Convertible Notes
Summary
CONMED has secured a $450 million delayed-draw term loan from JPMorgan to repurchase a portion of its 2.25% Convertible Senior Notes due in 2026. This financing addresses a significant debt maturity, as the company's recent 10-Q highlighted an $800 million convertible debt obligation. The proactive move helps manage the company's capital structure and reduces potential dilution from the convertible notes. The loan is available for draw until June 14, 2026, and matures in 2030.
At the time of this announcement, CNMD was trading at $35.70 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $33.21 to $60.35. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.